PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2048 Views
-
Last post by NHE
-
- 0 Replies
- 954 Views
-
Last post by NHE
-
- 0 Replies
- 9947 Views
-
Last post by NHE
-
- 0 Replies
- 1956 Views
-
Last post by Firidion
-
- 1 Replies
- 1339 Views
-
Last post by vesta
-
- 0 Replies
- 1983 Views
-
Last post by frodo
-
- 0 Replies
- 1898 Views
-
Last post by NHE
-
- 0 Replies
- 1485 Views
-
Last post by NHE
-
- 4 Replies
- 2404 Views
-
Last post by JohnC777